Articles On Kazia Therapeutics (ASX:KZA)

Australia has a well-regulated and high-quality health sector, while its medical research and healthcare infrastructure is of world class. Over the years, the health and medical industry in the country has grown at a rapid pace in terms of...

About 240,000 women are diagnosed with ovarian cancer each year worldwide and it is the eighth most common cause of cancer death in women.

Australian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) says it has completed recruitment of patients into Part B of its phase 1 clinical study of Cantrixil in ovarian cancer.

Companies and institutions that provide medical assistance and services, manufactures of medical equipment, engage in clinical trials and development of drugs, are part of the healthcare sector. The Australian government makes significant c...

Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of Kazia’s investigational new drug, GDC-0084.

Biotechnology company Kazia Therapeutics (ASX: KZA) has taken a definitive step towards proving the safety and efficacy of its investigational new drug GDC-0084, after announcing a “state of the art” phase 1 clinical trial to be conducted a...

Edison Investment Research has assigned an indicative valuation range of $84–135 million or $1.35–2.17 per share for Kazia.

Sydney-based Hishenk Pty Ltd now holds 10.835 million shares after placement and on-market purchases.

A new collaboration with the Alliance for clinical trials in oncology means Kazia will soon have four clinical trials of GDC-0084 underway in primary or secondary brain cancers.

The healthcare industry of Australia plays a major role in developing the country’s economy. The healthcare sector witnessed an increase in the demand for health services by Australia’s growing and ageing population. The growth in the indus...